---
trial_id: 543
discovery_date: 2022-04-10 16:23:54.515227
date: 2022-04-10 16:23:54.515227
title: "An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis"
summary: |
  <p>EudraCT Number: 2016-002937-31<br />Sponsor Protocol Number: MA30143<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2017-09-12<br />Medical condition: Relapsing remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NO">NO</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SI">SI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HR">HR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/IT">IT</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002937-31'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2016-002937-31<br />Sponsor Protocol Number: MA30143<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2017-09-12<br />Medical condition: Relapsing remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NO">NO</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SI">SI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HR">HR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/IT">IT</a> (Ongoing)</p>